Pre-made Nebacumab benchmark antibody (Whole mAb, anti-endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]/endotoxin therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Anti-endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]/endotoxin therapeutic antibody (Pre-made Nebacumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nebacumab is a human monoclonal antibody developed for the treatment of sepsis.[1] It has been withdrawn in 1993 because it failed to reduce mortality in clinical trials.[2]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-925-1mg	1mg	3090
GMP-Bios-INN-925-10mg	10mg	Inquiry
GMP-Bios-INN-925-100mg	100mg	Inquiry
GMP-Bios-INN-925-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nebacumab Biosimilar, Whole Mab: Anti-Endotoxin (Lipid A, Domain Of Lipopolyaccharide, Lps) [Gram Negative Bacteria] therapeutic antibody
INN Name	Nebacumab
Target	endotoxin (lipid A, domain of lipopolyaccharide, LPS) [gram negative bacteria]
Format	Whole mAb
Derivation	human
Species Reactivity	human
CH1 Isotype	IgM - kappa
VD LC	IgM - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	CSL Behring (King of Prussia PA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0